Richard Paulson, President and Chief Executive of Karyopharm Therapeutics Inc. Therapeutics, discusses their unique approach to cancer treatment that addresses a common mechanism of oncogenesis — dysregulation of nuclear export, as well as their therapeutic candidates.
.svg)
